Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) Net Margin (2016 - 2025)

Ultragenyx Pharmaceutical has reported Net Margin over the past 10 years, most recently at 62.02% for Q4 2025.

  • Quarterly Net Margin rose 1949.0% to 62.02% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 85.44% through Dec 2025, up 1635.0% year-over-year, with the annual reading at 85.44% for FY2025, 1635.0% up from the prior year.
  • Net Margin was 62.02% for Q4 2025 at Ultragenyx Pharmaceutical, up from 112.81% in the prior quarter.
  • Over five years, Net Margin peaked at 399.16% in Q4 2021 and troughed at 270.23% in Q3 2022.
  • The 5-year median for Net Margin is 124.89% (2021), against an average of 81.1%.
  • Year-over-year, Net Margin plummeted -54766bps in 2022 and then soared 53031bps in 2023.
  • A 5-year view of Net Margin shows it stood at 399.16% in 2021, then plummeted by -137bps to 148.5% in 2022, then surged by 357bps to 381.81% in 2023, then tumbled by -121bps to 81.51% in 2024, then rose by 24bps to 62.02% in 2025.
  • Per Business Quant, the three most recent readings for RARE's Net Margin are 62.02% (Q4 2025), 112.81% (Q3 2025), and 69.04% (Q2 2025).